Status
Conditions
Treatments
About
Background: In recent years, the changes of cognitive function in mild cognitive impairment have attracted attention.
Methods/design: We will follow up at 3. The primary outcome will be the measurement of cognitive function using neuropsychological assessment scales such as MOCA, MMSE, etc... Minor variables will be included plasma biomarkers (Aβ, Tau, GFAP, etc.), multimodal brain electrophysiology (P300, VP300, heart rate variability, etc.), and neuroimaging indicators (NODDI).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
200 participants in 1 patient group
Loading...
Central trial contact
Xiaodong Pan, Doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal